+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07743190

Personalized Anthracycline-Free Chemoimmunotherapy Using Carboplatin, Paclitaxel, and Pembrolizumab in Early-Stage Triple Negative Breast Cancer with High Tumor-Infiltrating Lymphocytes

Led by Medical University of South Carolina · Updated on 2026-10-15

55

Participants Needed

2

Research Sites

244 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new treatment approach for people with early-stage triple negative breast cancer TNBC whose tumors have a high level of immune cells called tumor-infiltrating lymphocytes TILs. This study aims to personalize treatment by using a regimen without anthracyclines, which are effective but carry risks, to see if patients with high TIL counts can avoid more toxic therapies while maintaining treatment effectiveness. The trial is a phase II non-inferiority study assessing whether this anthracycline-free approach is not significantly less effective than the current standard treatment. Participants will receive 12 weeks of chemotherapy with carboplatin and paclitaxel combined with the immunotherapy drug pembrolizumab before surgery, omitting anthracyclines during this neoadjuvant phase. After surgery, treatment depends on the pathologic response patients with no remaining cancer continue pembrolizumab alone, while those with residual cancer receive additional anthracycline-based chemotherapy plus pembrolizumab. Some patients may also receive other therapies like olaparib or capecitabine based on their doctors decision. Throughout the study, participants will undergo imaging, lab tests, and physical exams to monitor their condition and treatment response. Researchers will measure the rate of complete cancer response at surgery, event-free survival, overall survival, treatment side effects, and quality of life over several years. Patient-reported outcomes and biological markers will also be collected to better understand treatment effects. Participants will be followed for at least five years after treatment to assess long-term outcomes.

CONDITIONS

Brief Title

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

Research Team

H

HCC Clinical Trials Office

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here